miRecule is developing Antibody RNA Conjugate (ARC) therapeutics using its proprietary DREAmiR™ platform, which leverages genomic patient data to create targeted RNA therapies for cancer and muscular dystrophy. The company addresses genetic abnormalities by designing tailored therapeutics that aim to alleviate the debilitating symptoms associated with these disorders.
Funding
$47.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AVFounders
Product
Problem
Many cancers and muscular dystrophies are caused by underlying genetic abnormalities that are difficult to target with traditional therapies. Current treatment options often fail to address the root cause of these diseases, leading to debilitating symptoms and limited efficacy.
Solution
miRecule is developing Antibody RNA Conjugate (ARC) therapeutics designed to target and correct genetic abnormalities in cancer and muscular dystrophy patients. The company's DREAmiR™ platform leverages genomic and outcome data from thousands of patients to identify disease-causing genetic changes. miRecule then creates tailored RNA therapeutics that directly target and fix these abnormalities. The ARC approach combines the precision of antibody targeting with the therapeutic potential of RNA, delivering drugs specifically to affected tissues. This approach aims to provide more effective and personalized treatments for patients suffering from these disorders.
Target Audience
The primary target audience includes patients suffering from cancer and muscular dystrophy, as well as pharmaceutical companies seeking innovative RNA-based therapeutics.
Features
- DREAmiR™ platform utilizes genomic patient data to identify underlying genetic changes that cause disease
- Antibody RNA Conjugate (ARC) technology for targeted delivery of RNA therapeutics
- Development of first-in-class therapies for Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy (FSHD)
- RNA therapeutics designed to directly target and fix genetic abnormalities
- Conjugation platforms to create groundbreaking treatments